August 20th, 2020 | 08:29 CEST
EQS Group, EXMceuticals, Media and Games Invest - Buy recommendations from the experts
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Significant margin increase expected
EQS Group is a leading international technology provider for compliance and investor relations. With EQS Group, several thousand companies worldwide fulfill complex national and international disclosure requirements, minimize risks and address stakeholders in a targeted manner. EQS Group is a digital full service provider: Its products and services include a global newswire, a disclosure service, investor targeting and contact management, and insider list management. These are bundled in the cloud-based platform EQS COCKPIT to optimise the work processes of investor relations, communications and compliance officers.
The EQS Group continues to grow extremely dynamically and is gaining speed despite the Corona Crisis. Numerous factors are responsible for this positive development. The investment phase has now been completed and the company is focusing even more on profitable sales growth. All in all, EQS Group is very well positioned and should achieve significant profit increases due to the high proportion of recurring sales and the high scalability of the business model, according to analysts from GBC Research. The experts have raised their price target from EUR 91.50 to EUR 125.00 and maintain their 'Buy' rating.
Opportunity for high profit margins
EXMceuticals is a manufacturer of highly refined cannabis ingredients for the pharmaceutical, medical, nutraceutical and cosmetic industries. The company is preparing to enter the lucrative pharmaceutical market for CBD and other regulated cannabinoids on a B2B basis over the next 12 months. The company is focusing on the establishment and expansion of its Portuguese and European operations, in particular its existing R&D activities and the planned industrial refinery for cannabis ingredients near Lisbon.
EXMceuticals has completed the detailed planning for the equipment of an existing industrial plant in order to create a pharmaceutical quality factory that operates on a large scale and is certified according to EU GMP standards. The first production of medical ingredients from cannabis, including CBD, is expected once financing for the project is completed. Brightfield Group analysts forecast that the European CBD market will grow from EUR 373 million in 2019 to EUR 1.5 billion in 2023, with the global market expected to be worth EUR 14.4 billion by 2025. The analysts of Align Research have set a target price of CAD 0.958 in their latest study and assigned a 'Conviction Buy' rating.
Positive effects of COVID-19
Media and Games Invest plc has a profitable and growing portfolio of companies in the games and digital media sectors. The Group's primary objective is to grow through acquisitions, restructure and integrate companies into one large platform, and this strategy has so far produced a number of synergies including cost reductions, leverage and economies of scale. According to management, only a few competitors, particularly in the gaming sector, are pursuing this strategy, leaving room for acquisitions at a low price.
In the current COVID 19 pandemic, video games have once again proven to be crisis-proof and non-cyclical. As consumers had more leisure time, the demand for entertainment and thus for video games has risen sharply. The uncertainty surrounding the COVID 19 pandemic and its impact on the global economy remains difficult to predict. Although GBC Research's analysts remain cautious due to the volatility of the video games business, they remain fundamentally positive and have raised their price target from EUR 2.10 to EUR 2.85 and maintained their 'Buy' rating.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.